International registry of pediatric patients with recurrent or refractory hepatoblastoma or hepatocellular carcinoma.

This international multicenter registry [1] aims to collect data on the health of children with refractory or recurrent liver tumors. Patients with refractory or recurrent hepatoblastoma (HB), hepatocellular carcinoma (HCC), and unspecified hepatocellular neoplasm (HCN NOS) present, with current treatments, unsatisfactory long-term results. Furthermore, there is no generally accepted treatment for these patients. The aim of the RELIVE research project is to obtain an overview of past approaches and therapeutic strategies recently applied specifically in this context, and to study short- and long-term outcomes in these patients treated with these regimes. RELIVE thus seeks to identify the most promising therapeutic approaches with the ultimate aim of developing a clinical trial testing these approaches.

The RELIVE protocol was approved on September 21, 2020 by the Swiss Ethics Committee (EC). To date, RELIVE is active in 15 countries (Switzerland, Spain, France, Spain, France, France, France, France, Belgium, Belgium, Netherlands, Netherlands, Poland, Germany, United States, Canada, Japan, Japan, Canada, Japan, Japan, Japan, Australia, Japan, Australia, Japan, Australia, France, France, France, France, France, Belgium, Belgium, Netherlands, Netherlands, Netherlands, Netherlands, Poland, Germany A specific database, developed at the Geneva University Hospitals (HUG), allows data to be collected. Each active center has its own secure accesses and can thus enter the data of interest. As of May 2024, more than 360 children from 15 countries and 64 hospitals were enrolled in our international database. After an intense period of data verification at each of the centers, the analysis of this data is in progress.

The RELIVE project has also been presented at the SIOPE (International Society for Pediatric Oncology) and SIOPEL (International Society for Pediatric Oncology for Liver Cancer) congresses every year since spring 2021.

[1] https://relive-international.net

What does this study bring to patients?

The RELIVE project makes it possible to identify the most promising treatments to improve the prognosis of children with refractory or recurrent liver tumors, but also to set up scientific studies to optimize the understanding of this cancer and its management.